放射性肝病三级预防专家指导意见

摘要/Abstract

摘要： 随着肝癌等腹部肿瘤放射治疗疗效的提高,放射诱导的放射性肝病（radiation induced liver diseases, RILD）的临床矛盾日益突出。作为腹部肿瘤放射治疗的剂量限制性并发症之一,RILD目前尚无相关临床三级预防的共识。本文在阐明RILD发病机制的基础上,分三级归纳总结了RILD 防治的影响因素与相应防治措施,并给出专家指导意见,旨在让临床医师熟悉、掌握防治腹部肿瘤放射治疗过程中的潜在致命性RILD。

关键词: 肝癌, 放射治疗, 放射性肝病, 临床三级预防, 腹部肿瘤

Abstract: With the improvement of the efficacy of radiotherapy (RT) for abdominal tumors such as liver cancer, the clinical contradiction between the efficacy of RT and the occurrence of radiation-induced liver diseases (RILD) has become increasingly prominent. As one of the dose-limiting complications of abdominal tumor RT, RILD currently lacks a consensus on the clinical three-level prevention. On the basis of elucidating the pathogenesis of RILD, this article summarizes the influencing factors and corresponding prevention and treatment measures of RILD prevention and treatment in three levels, and provides expert guidance, summarizes the influencing factors and corresponding measures for RILD prevention and control at three levels, with the aim of enabling clinicians to be familiar with and master the potential fatal RILD during the RT process for abdominal tumors.

Key words: Liver cancer, Radiotherapy, Radiation induced liver diseases, Clinical three-level prevention, Abdominal tumor

吴志峰, 曾昭冲. 放射性肝病三级预防专家指导意见[J]. 肝癌电子杂志, 2025, 12(2): 1-7.

Wu Zhifeng, Zeng Zhaochong. Expert guidance on three-level prevention of radiation-induced liver diseases[J]. Electronic Journal of Liver Tumor, 2025, 12(2): 1-7.

参考文献

[1] 中华人民共和国国家卫生健康委员会医政司. 原发性肝癌诊疗指南(2024年版)[J/CD]. 肝癌电子杂志, 2024, 11(2):1-26.
[2] 中华人民共和国国家卫生健康委员会医政司. 原发性肝癌诊疗指南(2022年版)[J/CD]. 肝癌电子杂志, 2022, 9(1):1-22.
[3] PAN C C, KAVANAGH B D, DAWSON L A, et al.Radiation-associated liver injury[J]. Int J Radiat Oncol Biol Phys, 2010, 76(3 Suppl):S94-S100.
[4] MUNOZ-SCHUFFENEGGER P, NG S, DAWSON L A.Radiation-induced liver toxicity[J]. Semin Radiat Oncol, 2017, 27(4):350-357.
[5] ZENG Z C, TANG Z Y, FAN J, et al.A comparison of chemoembolization combination with and without radiotherapy for unresectable hepatocellular carcinoma[J]. Cancer J, 2004, 10(5):307-316.
[6] ALMAGHRABI M Y, SUPIOT S, PARIS F, et al.Stereotactic body radiation therapy for abdominal oligometastases: a biological and clinical review[J]. Radiat Oncol, 2012, 7: 126.
[7] ZHOU L Y, WANG Z M, GAO Y B, et al.Stimulation of hepatoma cell invasiveness and metastatic potential by proteins secreted from irradiated nonparenchymal cells[J]. Int J Radiat Oncol Biol Phys, 2012, 84(3):822-828.
[8] SUN W, MA J, WU S, et al.Characterization of the liver tissue interstitial fluid (TIF) proteome indicates potential for application in liver disease biomarker discovery[J]. J Proteome Res, 2010, 9(2):1020-1031.
[9] ZENG Z C, JIANG G L, WANG G M, et al.DNA-PKcs subunits in radiosensitization by hyperthermia on hepatocellular carcinoma hepG2 cell line[J]. World J Gastroenterol, 2002, 8(5):797-803.
[10] ZOIS C E, GIATROMANOLAKI A, SIVRIDIS E, et al.Narrow amifostine dose windows define radioprotection outcome, following fractionated whole-body irradiation of mice[J]. In Vivo, 2011, 25(2):191-196.
[11] 张薇, 高东伟, 朱向辉, 等. 大剂量低分割照射大鼠局部肝脏的早期实验研究[J]. 西南国防医药, 2011, 21(9):936-939.
[12] OLSEN C C, WELSH J, KAVANAGH B D, et al.Microscopic and macroscopic tumor and parenchymal effects of liver stereotactic body radiotherapy[J]. Int J Radiat Oncol Biol Phys, 2009, 73(5):1414-1424.
[13] WU Z F, ZHANG J Y, SHEN X Y, et al.A mouse radiation-induced liver disease model for stereotactic body radiation therapy validated in patients with hepatocellular carcinoma[J]. Med Phys, 2016, 43(7):4349.
[14] ICRP. ICRP statement on tissue reactions/early and late effects of radiation in normal tissues and organs-threshold doses for tissue reactions in a radiation protection context[J]. ICRP Publication 118. Ann. ICRP, 41(1/2).
[15] DU SS, ZENG Z C, TANG Z Y, et al.Regenerative capacity of normal and irradiated liver following partial hepatectomy in rats[J]. Int J Radiat Biol, 2009, 85(12):1114-1125.
[16] MARKS L B, YORKE E D, JACKSON A, et al.Use of normal tissue complication probability models in the clinic[J]. Int J Radiat Oncol Biol Phys, 2010, 76(3 Suppl):S10-S19.
[17] HSU C Y, WANG C W, CHENG A L, et al.Hypofractionated particle beam therapy for hepatocellular carcinoma-a brief review of clinical effectiveness[J]. World J Gastrointest Oncol, 2019, 11(8):579-588.
[18] HIROSHIMA Y, WAKATSUKI M, KANEKO T, et al.Clinical impact of carbon-ion radiotherapy on hepatocellular carcinoma with Child-Pugh B cirrhosis[J]. Cancer Med, 2023, 12(13):14004-14014.
[19] SU C W, HOU M M, HUANG P W, et al.Proton beam radiotherapy combined with anti-PD1/PDL1 immune checkpoint inhibitors for advanced hepatocellular carcinoma[J]. Am J Cancer Res, 2022, 12(4):1606-1620.
[20] PARK S H, KIM J C, KANG M K.Technical advances in external radiotherapy for hepatocellular carcinoma[J]. World J Gastroenterol, 2016, 22(32):7311-7321.
[21] HOU J Z, ZENG Z C, WANG B L, et al.High dose radiotherapy with image-guided hypo-IMRT for hepatocellular carcinoma with portal vein and/or inferior vena cava tumor thrombi is more feasible and efficacious than conventional 3D-CRT[J]. Jpn J Clin Oncol, 2016, 46(4):357-362.
[22] JIANG T, ZENG Z C, YANG P, et al.Exploration of superior modality: safety and efficacy of hypofractioned image-guided intensity modulated radiation therapy in patients with unresectable but confined intrahepatic hepatocellular carcinoma[J]. Can J Gastroenterol Hepatol, 2017: 6267981.
[23] DE LA PINTA A C. Radiation-induced liver disease in the era of SBRT: a review[J]. Expert Rev Gastroenterol Hepatol, 2020, 14(12):1195-1201.
[24] HU Y, ZHOU Y K, CHEN Y X, et al.4D-CT scans reveal reduced magnitude of respiratory liver motion achieved by different abdominal compression plate positions in patients with intrahepatic tumors undergoing helical tomotherapy[J]. Med Phys, 2016, 43(7):4335.
[25] URSINO S, GRECO C, CARTEI F, et al.Radiotherapy and hepatocellular carcinoma: update and review of the literature[J]. Eur Rev Med Pharmacol Sci, 2012, 16(11):1599-1604.
[26] CHANG W I, KIM B H, KIM Y J, et al.Role of radiotherapy in Barcelona Clinic Liver Cancer stage C hepatocellular carcinoma treated with sorafenib[J]. J Gastroenterol Hepatol, 2022, 37(2):387-394.
[27] LI H, WU Z, CHEN J, et al.External radiotherapy combined with sorafenib has better efficacy in unresectable hepatocellular carcinoma: a systematic review and meta-analysis[J]. Clin Exp Med, 2023, 23(5):1537-1549.
[28] BRADE A M, NG S, BRIERLEY J, et al.Phase 1 trial of sorafenib and stereotactic body radiation therapy for hepatocellular carcinoma[J]. Int J Radiat Oncol Biol Phys, 2016, 94(3):580-587.
[29] WANG H, ZHU X, ZHAO Y, et al.Phase 1 trial of apatinib combined with intensity-modulated radiotherapy in unresectable hepatocellular carcinoma[J]. BMC Cancer, 2022, 22(1):771.
[30] CHEN J, HE K, HAN Y, et al.Clinical efficacy and safety of external radiotherapy combined with sorafenib in the treatment of hepatocellular carcinoma: a systematic review and meta-analysis[J]. Ann Hepatol, 2022, 27(4):100710.
[31] LI J X, SU T S, GONG W F, et al.Combining stereotactic body radiotherapy with camrelizumab for unresectable hepatocellular carcinoma: a single-arm trial[J]. Hepatol Int, 2022, 16(5):1179-1187.
[32] MUNOZ-SCHUFFENEGGER P, BARRY A, ATENAFU E G, et al.Stereotactic body radiation therapy for hepatocellular carcinoma with macrovascular invasion[J]. Radiother Oncol, 2021, 156: 120-126.
[33] CHIANG C L, CHIU K, CHAN K, et al.Sequential transarterial chemoembolisation and stereotactic body radiotherapy followed by immunotherapy as conversion therapy for patients with locally advanced, unresectable hepatocellular carcinoma (START-FIT):a single-arm, phase 2 trial[J]. Lancet Gastroenterol Hepatol, 2023, 8(2):169-178.
[34] CHIANG C L, CHAN A, CHIU K, et al.Combined stereotactic body radiotherapy and checkpoint inhibition in unresectable hepatocellular carcinoma: a potential synergistic treatment strategy[J]. Front Oncol, 2019, 9: 1157.
[35] YX C, P Y, DU SS, et al. Stereotactic body radiotherapy combined with sintilimab in patients with recurrent or oligometastatic hepatocellular carcinoma: a phaseⅡclinical trial[J]. World J Gastroenterol, 2023, 29(24):3871-3882.
[36] CHENG J C, LIU H S, WU J K, et al.Inclusion of biological factors in parallel-architecture normal-tissue complication probability model for radiation-induced liver disease[J]. Int J Radiat Oncol Biol Phys, 2005, 62(4):1150-1156.
[37] CHOU C H, CHEN P J, LEE P H, et al.Radiation-induced hepatitis B virus reactivation in liver mediated by the bystander effect from irradiated endothelial cells[J]. Clin Cancer Res, 2007, 13(3):851-857.
[38] DAWSON L A, NORMOLLE D, BALTER J M, et al.Analysis of radiation-induced liver disease using the Lyman NTCP model[J]. Int J Radiat Oncol Biol Phys, 2002, 53(4):810-821.
[39] LIANG S X, ZHU X D, XU Z Y, et al.Radiation-induced liver disease in three-dimensional conformal radiation therapy for primary liver carcinoma: the risk factors and hepatic radiation tolerance[J]. Int J Radiat Oncol Biol Phys, 2006, 65(2):426-434.
[40] 中华医学会放射肿瘤学分会,中国生物医学工程学会精确放疗分会肝癌学组与消化系统肿瘤专家委员会,中国研究型医院学会放射肿瘤学分会肝癌学组. 2016年原发性肝癌放疗共识[J]. 中华放射肿瘤学杂志, 2016, 25(11):1141-1150.
[41] BAE S H, PARK H C, YOON W S, et al.Treatment outcome after fractionated conformal radiotherapy for hepatocellular carcinoma in patients with Child-Pugh classification B in Korea (KROG 16-05)[J]. Cancer Res Treat, 2019, 51(4):1589-1599.
[42] DUBUISSON J, COSSET F L.Virology and cell biology of the hepatitis C virus life cycle: an update[J]. J Hepatol, 2014, 61(1 Suppl):S3-S13.
[43] ZUO C, XIA M, WU Q, et al.Role of antiviral therapy in reducing recurrence and improving survival in hepatitis B virus-associated hepatocellular carcinoma following curative resection (review)[J]. Oncol Lett, 2015, 9(2):527-534.
[44] KIM J, JUNG Y.Radiation-induced liver disease: current understanding and future perspectives[J]. Exp Mol Med, 2017, 49(7):e359.
[45] 张成祥. 拉米夫定联合三维适形放疗治疗原发性肝癌36例[J]. 江苏医药, 2008, 34(12):1295-1296.
[46] LI Z, DONG Y, FAN M, et al.Analysis of hepatitis B virus Reactivation after radiotherapy in patients with hepatocellular carcinoma using the lyman NTCP Model[J]. Technol Cancer Res Treat, 2019, 18: 1078142784.
[47] KIM J H, PARK J W, KIM T H, et al.Hepatitis B virus reactivation after three-dimensional conformal radiotherapy in patients with hepatitis B virus-related hepatocellular carcinoma[J]. Int J Radiat Oncol Biol Phys, 2007, 69(3):813-819.
[48] HUANG W, ZHANG W, FAN M, et al.Risk factors for hepatitis B virus reactivation after conformal radiotherapy in patients with hepatocellular carcinoma[J]. Cancer Sci, 2014, 105(6):697-703.
[49] JUN B G, KIM Y D, KIM S G, et al.Hepatitis B virus reactivation after radiotherapy for hepatocellular carcinoma and efficacy of antiviral treatment: a multicenter study[J]. PLoS One, 2018, 13(7):e201316.
[50] PAPATHEODORIDI M, TAMPAKI M, LOK A S, et al.Risk of HBV reactivation during therapies for HCC: a systematic review[J]. Hepatology, 2022, 75(5):1257-1274.
[51] ANGELIDAKIS G, KRISHNAN S, CABRERA N L, et al.Virologic impact of radiotherapy in hepatitis C virus-infected patients with hepatocellular carcinoma[J]. Hepatology, 2020.
[52] ZHOU J, SUN H, WANG Z, et al.Guidelines for the diagnosis and treatment of hepatocellular carcinoma (2019 edition)[J]. Liver Cancer, 2020, 9(6):682-720.
[53] GARRA B S, SHAWKER T H, CHANG R, et al.The ultrasound appearance of radiation-induced hepatic injury. Correlation with computed tomography and magnetic resonance imaging[J]. J Ultrasound Med, 1988, 7(11):605-609.
[54] HERFARTH K K, HOF H, BAHNER M L, et al.Assessment of focal liver reaction by multiphasic CT after stereotactic single-dose radiotherapy of liver tumors[J]. Int J Radiat Oncol Biol Phys, 2003, 57(2):444-451.
[55] HOWELLS C C, STINAUER M A, DIOT Q, et al.Normal liver tissue density dose response in patients treated with stereotactic body radiation therapy for liver metastases[J]. Int J Radiat Oncol Biol Phys, 2012, 84(3):e441-e446.
[56] STINAUER M A, DIOT Q, WESTERLY D C, et al.Fluorodeoxyglucose positron emission tomography response and normal tissue regeneration after stereotactic body radiotherapy to liver metastases[J]. Int J Radiat Oncol Biol Phys, 2012, 83(5):e613-e618.
[57] GUHA C, KAVANAGH B D.Hepatic radiation toxicity: avoidance and amelioration[J]. Semin Radiat Oncol, 2011, 21(4):256-263.
[58] SANUKI-FUJIMOTO N, TAKEDA A, OHASHI T, et al.CT evaluations of focal liver reactions following stereotactic body radiotherapy for small hepatocellular carcinoma with cirrhosis: relationship between imaging appearance and baseline liver function[J]. Br J Radiol, 2010, 83(996):1063-1071.
[59] ZENG Z C, SEONG J, YOON S M, et al.Consensus on stereotactic body radiation therapy for small-sized hepatocellular carcinoma at the 7th Asia-Pacific Primary Liver Cancer Expert Meeting[J]. Liver Cancer, 2017, 6(4):264-274.
[60] 国家卫生健康委办公厅. 原发性肝癌诊疗指南(2022年版)[J/CD]. 中华普通外科学文献(电子版), 2022, 16(2):81-96.
[61] KOAY E J, OWEN D, DAS P.Radiation-induced liver disease and modern radiotherapy[J]. Semin Radiat Oncol, 2018, 28(4):321-331.
[62] FENG M, SMITH D E, NORMOLLE D P, et al.A phase I clinical and pharmacology study using amifostine as a radioprotector in dose-escalated whole liver radiation therapy[J]. Int J Radiat Oncol Biol Phys, 2012, 83(5):1441-1447.
[63] PING X, JUNQING J, JUNFENG J, et al.Radioprotective effects of troxerutin against gamma irradiation in mice liver[J]. Int J Radiat Biol, 2012, 88(8):607-612.
[64] GRDINA D J, MURLEY J S, KATAOKA Y, et al.Amifostine induces antioxidant enzymatic activities in normal tissues and a transplantable tumor that can affect radiation response[J]. Int J Radiat Oncol Biol Phys, 2009, 73(3):886-896.
[65] 赵增虎, 刘俊堂, 范青建. 放射性肝损伤研究及防治进展[J]. 现代肿瘤医学, 2011, 19(10):2110-2113.
[66] GUYATT G H, OXMAN A D, VIST G E, et al.GRADE: an emerging consensus on rating quality of evidence and strength of recommendations[J]. BMJ, 2008, 336(7650):924-926.